针对PCSK9来应对心血管疾病
Sandra Hummelgaard1, Joachim Pold Vilstrup2, Camilla Gustafsen2
1Department of Biomedicine, Aarhus University, Aarhus, Denmark.
Pharmacology & therapeutics
|June 18, 2023
概括
使用PCSK9抑制剂降低血胆固醇有效降低心血管疾病的风险. 这些疗法向PCSK9,这是LDL受体降解的关键调节者,为管理高胆固醇血症提供了一种新的方法.
科学领域:
- 生物化学 生物化学
- 遗传学 是一个遗传学.
- 心血管医学 心血管医学
背景情况:
- 动脉样硬化心血管疾病 (ASCVD),包括冠状动脉疾病 (CAD),是全球死亡的主要原因,由动脉中胆固醇斑块形成驱动.
- 蛋白转化酶亚素素/9型 (PCSK9) 是胆固醇代谢的关键调节者,控制肝脏中低密度脂蛋白 (LDL) 受体水平.
研究的目的:
- 审查PCSK9生物学,包括其结构和遗传突变.
- 详细阐述当前和正在开发的降低PCSK9的治疗策略.
- 讨论PCSK9抑制在心血管疾病之外的未来应用.
主要方法:
- 关于PCSK9生物学,遗传学和治疗开发的科学文献的综述.
- 对已批准和正在研究的PCSK9抑制剂的临床数据的分析.
- 探索推动治疗设计的结构和遗传洞察力.
主要成果:
- 功能增益的PCSK9突变会导致家族性高胆固醇血症,导致高LDL-C和ASCVD风险.
- 功能丧失的PCSK9突变与低的LDL-C和CAD保护有关.
- 已批准的基于抗体的PCSK9抑制剂有效降低LDL-C和ASCVD事件,具有有利的安全性.
结论:
- PCSK9是降低LDL-C和降低心血管风险的有效治疗标.
- PCSK9抑制剂在治疗高胆固醇血症和预防ASCVD方面取得了重大进展.
- 对PCSK9抑制的进一步研究有望用于治疗其他严重疾病.
相关概念视频
Coronary Artery Disease IV: Preventive Measures
25
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
25
Atherosclerosis III: Management
15
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
15
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
713
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
713
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
212
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
212
Coronary Artery Disease I: Introduction
33
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
33
Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K


